Focada exclusivamente no desenvolvimento, 
                                        produção e promoção de produtos farmacêuticos especializados

Notice to the Market – HARVONI® approved in Brazil


Grupo Biotoscana expects to introduce the product into the market in Q2 2018.

Montevideo, Uruguay, December 5, 2017. GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces HARVONI® (90 mg ledipasvir / 400 mg sofosbuvir) approval by ANVISA, in Brazil. The last step of the registration process is price approval by CMED.

GBT will be responsible for market access, commercialization, distribution in Brazil. Gilead Sciences will continue to be responsible for supplying these treatment options directly to the Brazilian Ministry of Health.

GBT is very enthusiastic to be able to expand this existing partnership and broaden the HCV treatment options by adding leading brand HARVONI® to better serve more patients and doctors with this serious infectious disease, explains Mariano García-Valiño, CEO of GBT.

GBT – Grupo Biotoscana.
Melissa Angelini
IR Manager
Tel.: +55 11 5090 5923

To access the PDF version, please click here.

Updated on 01/02/2019 at 04:49 pm